Research Highlights Antioxidant Potential for Preeclampsia Relief
Understanding Preeclampsia
A recent study involving rats indicates that an antioxidant found in mushrooms may alleviate certain symptoms of preeclampsia, a condition characterized by pregnancy-related high blood pressure. Preeclampsia typically arises after the 20th week of pregnancy, with blood pressure readings exceeding 140 mm Hg/90 mm Hg. This condition affects approximately five to seven percent of pregnant women globally, posing significant risks to both the mother and child, including premature births and cesarean deliveries.
Diagnosis and Symptoms
The diagnostic criteria for preeclampsia include a decrease in blood platelets following pregnancy, fluid accumulation in the lungs, and complications affecting the kidneys, liver, or brain, such as seizures or visual disturbances. Common symptoms encompass headaches, abdominal pain, shortness of breath, confusion, and visual issues like light sensitivity and blurred vision. It is crucial for expectant mothers experiencing these symptoms to consult with their healthcare providers.
Causes and Mechanisms
The underlying causes of preeclampsia remain inadequately understood. Researchers believe that abnormalities in placental development and the blood vessel adaptations necessary during pregnancy contribute to this condition. Insufficient blood flow to the fetus can lead to oxidative stress, which subsequently causes inflammation and constriction of small arteries in the mother. Studies have identified elevated oxidative stress markers in the placental tissue of preeclamptic pregnancies, with mitochondrial dysfunction increasingly recognized as a contributor to the oxidative stress associated with preeclampsia.
Antioxidants and Their Effectiveness
Clinical trials investigating the use of antioxidants for treating preeclampsia have yielded limited success. Previous antioxidants may not have effectively targeted mitochondria, which are a source of oxidative stress in this condition. Collaborative research conducted by teams from University College Cork, University of Liverpool, and the Technical University of Denmark has revealed promising therapeutic effects of L-ergothioneine, an unusual amino acid, in reducing some preeclampsia symptoms in rat models. The findings were published in the journal *Hypertension*.
Study Findings
The administration of L-ergothioneine to rat models with preeclampsia resulted in several positive outcomes, including:
– Restoration of birth weights to levels similar to control groups
– Decreased levels of the compound slFt-1, which inhibits blood vessel growth
– A two to five-fold increase in the expression of antioxidant mitochondrial detoxifying enzymes
Dr. Cathal McCarthy, the lead researcher, emphasized the significance of the study, stating, “Our research shows that treating rats with pre-eclampsia with the natural antioxidant L-ergothioneine reduced blood pressure, prevented fetal growth restriction, and dampened production of the damaging substances released from the placenta during pre-eclampsia.” The study also utilized a novel method to demonstrate how decreased blood flow to the placenta leads to heightened mitochondrial-specific oxidative stress, further implicating mitochondrial dysfunction in preeclampsia development.
L-Ergothioneine: A Natural Antioxidant
L-ergothioneine (ERG) is a water-soluble amino acid exclusively obtained from dietary sources, with high concentrations found in mushrooms, kidney beans, and black beans. Dr. Douglas Kell from DTU Biosustain, University of Liverpool, noted, “Today, ergothioneine is either made chemically or extracted from mushrooms, but at DTU Biosustain we are developing a method to make it biologically. This should lead to its much wider availability at competitive prices.” Preclinical studies using rat models have indicated that ERG is well-tolerated and does not produce adverse effects in pregnant rats. While ERG shows promise as a naturally derived antioxidant with potential therapeutic benefits for treating preeclampsia, further validation through human clinical trials is necessary.
References
– Williamson RD, McCarthy FP, Manna S, Groarke E, Kell DB, Kenny LC, McCarthy CM. L-(+)-Ergothioneine Significantly Improves the Clinical Characteristics of Preeclampsia in the Reduced Uterine Perfusion Pressure Rat Model. *Hypertension*. 2020 Feb;75(2):561-568.
– Prevalence of preeclampsia – Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and Perspectives. *Circ Res*. 2019 Mar 29;124(7):1094-1112.
– Symptoms of preeclampsia – https://www.preeclampsia.org/health-information/faqs/